ARTICLE | Company News
GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix
September 14, 2018 3:18 PM UTC
GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic colorectal cancer (mCRC) Vectibix panitumumab.
GNS will use its AI platform Reverse Engineering & Forward Simulation (REFS) to create causal models using combined data from Amgen's Phase II PEAK trial and the alliance's Phase III CALGB 80405 trial...
BCIQ Target Profiles